Versant Capital Management
AVIR icon

Versant Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Versant Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.9K Buy
4,397
+177
+4% +$905 ﹤0.01% 1885
2026
Q2 		$19.6K Buy
+4,220
New +$21K ﹤0.01% 1939

Other funds holding AVIR

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Auour Investments
Auour Investments Woburn, Massachusetts $353M AUM 8.66% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Versant Capital Management's AVIR Position: Q3 2026 in Review

Versant Capital Management increased its Atea Pharmaceuticals (AVIR) stake by 4.2% in Q3 2026, buying an estimated $905 and bringing the position to 4,397 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

Versant Capital Management first reported a position in AVIR in Q2 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • Versant Capital Management held 4,397 shares of Atea Pharmaceuticals worth $22.9K as of Q3 2026.
  • Versant Capital Management bought 177 Atea Pharmaceuticals shares in Q3 2026, an estimated $905.
  • Atea Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1885 holding.
  • Versant Capital Management first reported a position in Atea Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.